Association Between ABCB1 Gene Polymorphism with Hyperglycemia and MACE in Patients Undergoing Clopidogrel Treatment After PCI.

Purpose: To evaluate the effect of C3435T gene polymorphism with hyperglycemia on the risk of major adverse cardiovascular events (MACE) in patients treated with clopidogrel after percutaneous coronary intervention (PCI).

Patients And Methods: A total of 117 patients were studied, of which 52 developed MACE. We used fluorescence in situ hybridization to detect the genotype of the and C3435T loci. Baseline characteristics, fasting blood glucose, and clinical outcomes were collected. Logistic regression was used to analyze factors influencing MACE in PCI patients treated with clopidogrel.

Results: There were significant differences between normal and MACE groups in gender, age, history of diabetes mellitus, history of alcohol consumption, fasting blood glucose, (CC) with normoglycemia, and (CT/TT) combined with hyperglycemia ( < 0.05). C3435T genotype (= 0.024, OR = 5.584, 95% CI 1.258-24.780), age (= 0.014, OR = 1.073, 95% CI 1.014-1.135), History of hypertension (= 0.020, OR = 3.144, 95% CI 1.200-8.238) and History of diabetes mellitus (= 0.030, OR = 3.731, 95% CI 1.135-12.270) were independent MACE risk factors. In patients <75 years, history of hypertension (= 0.021, OR = 3.151, 95% CI 1.189-8.350) was a risk factor, while the (CC) with normoglycaemia (= 0.023, OR = 0.147, 95% CI 0.028-0.767) was a protective factor.

Conclusion: The C3435T genotype is an independent risk factor for MACE after PCI with clopidogrel therapy. CC combined normoglycemia may protect against MACE in patients <75 years.

Trial Registration: Registration number: ChiCTR2400082012, Reg Date: 2024-03-19.